The Long-Term Safety and Tolerability of ABT-089 in Children With Attention Deficit-Hyperactivity Disorder (ADHD): An Open-Label Extension Study.
Phase of Trial: Phase II
Latest Information Update: 09 Aug 2016
At a glance
- Drugs Pozanicline (Primary)
- Indications Attention-deficit hyperactivity disorder
- Focus Therapeutic Use
- Sponsors Abbott Laboratories
- 14 Sep 2008 Actual patient number (283) added as reported by ClinicalTrials.gov.
- 14 Sep 2008 Status changed from recruiting to discontinued as reported by ClinicalTrials.gov.
- 01 Jan 2008 Status changed from initiated to recruiting.